A novel therapy that combines a muscarinic receptor agonist with an anticholinergic agent is associated with a greater reduction in psychosis symptoms compared with placebo, new research shows. In a randomized...

The coronavirus disease 2019 (COVID-19) pandemic has claimed well over 2.4 million lives, but its long-term sequelae are still being identified. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

(HealthDay)—In young people at risk for psychosis, proteomic biomarkers may help to individualize prognosis, according to a study published online Aug. 26 in JAMA Psychiatry. David Mongan, M.B., B.Ch.,...